New oral option for TGCT when surgery poses risks

• by Teraya Smith

• November 10, 2026

FDA revises monitoring for SCLC therapy

Initial monitoring decreases from 22 to 24 hours to 6 to 8 hours from the start of the first 2 infusions.

• by Kathryn Wighton

• September 15, 2026

• 2 min

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

• by Andrea Surnit

• September 3, 2026

• 4 min